Skip to main content

Tag: United Kingdom

UK Study Finds Cannabis Consumption Is Not Linked To Changes In Motivation

Historically, cannabis consumers have been portrayed by cannabis opponents as lazy ‘do nothings’ that sit on couches all day eating potato chips. Those stereotypes have also been perpetuated in mainstream media.

Unfortunately for cannabis opponents, there are numerous examples of people in peak physical condition that consume cannabis every single day, as demonstrated by the growing number of professional athletes that are coming out of the cannabis closet.

To be fair, there are certainly cannabis consumers that lack motivation, however, it’s not because of the cannabis. Some people are just lazy. That is reflected in the results of a recent study out of the United Kingdom. Below is more information about it via a news release from NORML:

London, United Kingdom: Neither adults nor young people who consume cannabis exhibit symptoms of so-called ‘a-motivational syndrome,’ according to case control data published in The International Journal of Neuropsychopharmacology.

British researchers assessed apathy, anhedonia (an inability to feel pleasure), and effort-based decision making in a cohort of late-adolescent and young adult cannabis consumers. Their performance was compared to that of age-matched controls (non-cannabis consumers).

Researchers identified no significant differences between the two groups.

“Cannabis use has historically been linked with a-motivation, which is reflected in prevalent, pejorative ‘lazy stoner’ stereotypes. In this study, we counter this cliché by showing that a relatively large group of adult and adolescent cannabis users and controls did not differ on several measures of reward and motivation,” they concluded. “Specifically, people who used cannabis on average four days per week did not report greater apathy or anhedonia, reduced willingness to expend effort for reward, or reduced reward wanting or liking compared to people who did not use cannabis. … Our results add to the growing body of evidence suggesting that non-acute cannabis use is not linked with amotivation, which may help to reduce stigma experienced by people who use cannabis.”

The investigators’ findings are consistent with those of other recent studies refuting long standing claims that those with a history of marijuana use typically lack motivation.

Full text of the study, “Anhedonia, apathy, pleasure, and effort-based decision-making in adult and adolescent cannabis users and controls,” appears in The International Journal of Neuropsychopharmacology.

Liz Truss Makes It Clear Where She Stands On Cannabis Policy

Cannabis reform is one of the most popular political issues on earth right now, particularly in North America and Europe. At a time when it seems like people rarely agree on anything, cannabis is one area of public policy where support is strong and cuts across party lines. Unfortunately, that support does not appear to extend to the office of the United Kingdom’s Prime Minister, with the UK announcing this week that it is officially blocking a cannabis reform measure that was previously passed by lawmakers in Bermuda earlier this year.

Liz Truss took over as Prime Minister in the United Kingdom this week, and shortly after taking office her government announced the official blockage of the cannabis reform measure in Bermuda. Cannabis policy observers around the globe were hopeful that upon taking office that Truss would pursue a new era for cannabis policy in the UK, however, being that she is blocking cannabis reform elsewhere it’s very clear where she stands when it comes to cannabis policy.

Actions Speak Louder Than Words

Truss, like many politicians, has a checkered past when it comes to cannabis policy. Leading up to the Prime Minister transition in the UK, Truss was criticized by opponents for her previously expressed support for cannabis reform. Apparently, a leaflet edited by Liz Truss when she was a leading Lib Dem at Oxford University surfaced in which it was asked if cannabis should be legalized, a position that Truss reportedly supported back then.

The newly installed Prime Minister has been criticized by both cannabis supporters and opponents for ‘flip flopping’ on the issue, with many asking the logical question, ‘where does Liz Truss really stand when it comes to cannabis reform?’ Unfortunately, we found out the answer to that question this week, and it wasn’t a favorable answer.

Politicians of all backgrounds and at all levels will often tell voters what they think they want to hear. It is no secret that many people who seek public office will say whatever it takes to get elected, even if what they are saying to one audience completely contradicts what they are telling a different audience. That is politics as usual, and the real measure of a politician on any given issue is what actions they take (or do not take) once they get into a position to actually do something regarding the particular issue.

Colonization on Full Display

In order for cannabis reform to move forward in Bermuda, the measure has to receive blessing from the United Kingdom in the form of ‘royal assent.’ It’s a concept that is born out of the United Kingdom’s (Britain) colonization of Bermuda centuries ago. Bermuda remains the oldest British colony in existence, which in itself needs to be addressed.

Lawmakers in Bermuda deserve to set their own laws. No one in the United Kingdom should be able to prevent a law from taking effect in Bermuda, whether it’s related to cannabis or anything else. Citizens in Bermuda elect their own representatives, and those representatives should be able to carry out ‘the people’s work’ without interference from countries across the Atlantic Ocean.

Fortunately, it sounds like lawmakers in Bermuda are going to proceed forward with their plans despite the opposition by Liz Truss’ government. It sets up a constitutional showdown between the UK and Bermuda, and in the first week of Truss’ tenure as Prime Minister no less. With all of the problems out there in the world, it’s a shame that any time and effort is being spent on preventing the will of Bermuda’s citizens. The only ‘benefit’ to the saga is that it makes clear where Liz Truss stands on cannabis policy, for better or worse.

UK’s Top Contender For Prime Minister Criticized For U-Turn On Cannabis Reform

In an increasingly bitter and close race, Tory rival for the top political job, Rishi Sunak has criticized Liz Truss for her flip-flop on cannabis reform

The current political battle in the UK to replace Boris Johnson has gotten increasingly nasty if not out of touch with the issues that most people are now facing. The top two rivals for the Prime Minister’s office, have been slugging away at each other’s policies for weeks now.

Given this, it was inevitable that the issue of cannabis reform would surface, in some form.

Now Rishi Sunak, dubbed “Dishy Rishi” by his detractors, who would become not only the first non-white Prime Minister but the first practicing Hindu to hold the office, has gone there. Specifically, he has attacked Liz Truss, his opponent, for once supporting cannabis reform – when she was a student at Oxford and the one-time president of the Oxford Liberal Democrats.

Interestingly, Sunak, who also spent time in California while attending Stanford University to obtain an MBA degree, is not taking a stand on cannabis reform, even of the medical kind. His criticism is that Truss is a politician who will flip flop to gain political advantage and holds no fixed beliefs. She currently opposes cannabis reform as a member of the Tory party.

It is the kind of campaign not seen (yet) in the United States or Germany – two countries where the issue of federal cannabis reform is now looming. It is also a sign of how far even medical cannabis reform still has to go in the UK – forget full legalization.

Where Cannabis Reform Now Stands in Britain

The UK is now suffering from high inflation, post-Brexit woes, and a political discussion that has been warped beyond recognition because of the same. As literally millions of Britons are suffering from energy costs that have increased dramatically this year plus food and medicine shortages, the Tory leadership battle has focussed on esoteric issues that have little to do with the major problems now faced by the majority of the country.

In the meantime, the government is at a literal standstill under the lame duck tenancy of Boris Johnson, who was forced out by members of his own party after one too many scandals earlier this summer.

The issue of cannabis reform is, as a result, unlikely to become a political force on a national level in this kind of environment. Indeed, it has stagnated all over the country, even in places like the Channel Islands where local support had gelled for proceeding.

It is unlikely that the UK will be able to hold out forever, no matter who wins the current leadership contest. Indeed, it will be a potent political issue in the next national election, due to be held in the next several years.

Until then, however, look for the same old, tired excuses for failing to enact more comprehensive policies from the Tory party as cannabis patients continue to suffer and people are convicted of criminal charges even for small amounts of cannabis. There are currently an estimated 17,000 “legal” cannabis patients in Britain.

UK’s Lack Of Comprehensive Cannabis Policy Criticized

A Report Launched by UK Minister for Science, Research and Innovation criticizes a lack of coordinated policy on “cannabinoid innovation”

The UK government is criticizing itself in a new report to be launched by the Minister of Science, Research, and Innovation – namely calling on the government to turbocharge cannabis innovation rather than continuing to take a disinterested approach to the sector.

It also explicitly criticizes the approach so far.

According to the report, “It is not sustainable or acceptable for the [UK] Government to continue to take an uncoordinated, disinterested or laissez-faire attitude to the sector as a whole, as it has done since the cannabis sector’s 2018 inception.”

The 24-page document quotes leading industry players, academics, patients, consumers, and investors.

Beyond being critical of the progress so far, however, the report also lists twenty ways in which the UK can create a best-in-class cannabis sector.

Commissioned by the Centre for Medicinal Cannabis and the Association for the Cannabinoid Industry, the report was authored by Professor Christopher Hodges, a well-known regulatory expert, and thought leaders. The work will also be launched with a speech from George Freeman, a member of parliament and the minister of the agency which is ultimately responsible for the report.

It is, as a result, the first-ever ministerial address about the cannabis sector in the UK.

Evolving By Accident

According to the report, the market has “evolved by accident, without coordinated government action or a coherent strategy to steward it to maturity.” They further offer some interesting findings including that 1 in 7 Britons use cannabis for medical if not health reasons and that 64% of the population believes that scientific study of cannabinoids should be supported by the government.

A New Regulatory Schemata

Arguing that the framework established by the report would create a global advantage for post-Brexit Britain, Professor Hodges, an Emeritus Professor of Justice Systems at the Centre for Socio-Legal Studies at Oxford, also calls for specific changes that could be made quickly and easily.

These include allowing GPs to prescribe medical cannabis rather than specialists, modernizing the Proceeds of Crime Act, creating a national patient registry, and updating the rules about farming hemp. The report also calls for the creation of a “stewarding authority” to implement the suggested reforms as well as govern and guide the sector forward.

Through these suggestions, the report authors hope to create jobs, attract more investment, and secure both political support and public recognition.

London Mayor Launches Commission To Examine Cannabis Policy

Cannabis reform is sweeping the European continent, with at least one country now a legal jurisdiction for adult use. Late last year Malta became the first country in Europe to pass an adult-use legalization measure.

Italy was on track to possibly legalize cannabis this year after activists gathered and submitted over 630,000 signatures in an attempt to put legalization in front of voters. Unfortunately, even though the effort proved to have gathered enough valid signatures Italy’s government stopped the effort in its tracks, claiming that it was unconstitutional to let it proceed.

Cannabis legalization pilot programs are starting to spread across Europe. Copenhagen already has a program underway and the pilot program is set to expand across Denmark as more jurisdictions sign up. Switzerland is launching its first pilot program site in Basel this summer, and hopefully by 2023, the Netherlands will do the same.

Germany’s governing coalition previously announced plans to legalize cannabis in the near future, and last week Germany’s Health Minister announced that the timeline for legalization would be sped up with legalization possibly coming as soon as this summer.

In the midst of all of the momentum for cannabis reform on the continent one country that has moved almost as slow as any other nation is the United Kingdom. The UK’s medical cannabis program is extremely limited and has only helped a minor fraction of the number of suffering patients that exist in the UK. Recreational cannabis possession and use remain prohibited.

London’s Mayor, Sadiq Khan, announced this week that a commission will be launched to explore, among other things, cannabis policy reform. Per The Guardian:

Sadiq Khan has announced a commission to examine the effectiveness of the UK’s drug laws, with a particular focus on those governing cannabis.

The London drugs commission, to be chaired by Lord Charlie Falconer QC, a former lord chancellor and justice secretary, was one of Khan’s manifesto pledges in his re-election bid last year.

The mayor of London’s office said a panel of independent experts in criminal justice, public health, politics, community relations and academia will be assembled to consider evidence from around the world on the outcomes of various drug policies.

The announcement was made while Khan was in Los Angeles where he toured a cannabis cultivation facility. The announcement of the commission yielded swift pushback from the Home Secretary of the United Kingdom Priti Patel. Per The Times:

The home secretary has criticised the mayor of London after he set up a commission to consider the decriminalisation of cannabis.

Priti Patel told Sadiq Kahn that he “has no powers to legalise drugs”.

“Sadiq Khan’s time would be better spent focusing on knife and drug crime in London. The mayor has no powers to legalise drugs. They ruin communities, tear apart families and destroy lives,” Patel said in a tweet.

For starters, the War on Drugs ruins communities, tears apart families, and destroys lives. That is a fact. It is also a fact that the War on Drugs has failed, both in the United Kingdom and beyond. Patel’s tweet obviously disregards those facts.

Secondly, as I understand it, what Khan has proposed is essentially a fact-finding commission, not a commission that will actually seek to change policies. I suppose that it could evolve to a point where that is being pursued, however, that does not appear to be the case right now.

What does appear to be the case, at least in my opinion, is that Patel and other like-minded officials are probably scared of what the commission will potentially find and publish. It’s much easier for Patel and others to peddle reefer madness rhetoric without the existence of a commission like the one that Khan is launching.

UK Government Fund Invests In Cannabis Company

During the pandemic, the United Kingdom set up a fund called the ‘British Business Bank’s Future Fund.’ The aim of the taxpayer-backed fund was to ‘support innovative companies that might have struggled to secure money during the pandemic.’

The fund recently announced another round of applicant approvals, and among the winners of the government investments was a cannabis company that specializes in making hemp-derived oil. Per excerpts from The Guardian:

The UK government has become a shareholder in a cannabis oil company, a yoghurt bar business, a London-based craft brewery and a maker of land, underwater and air drones that “take inspiration from the clever tricks that animals use to move”.

The latest round of investments include Grass & Co, founded by brothers Ben and Tom Grass in 2019, which makes cannabidiol (CBD) products using chemicals found in hemp, which are stocked in stores including Selfridges and Boots.

According to coverage by The Guardian, the fund has shelled out over £1.4 billion to a total of 1,190 companies so far, with 335 of those companies converting government loans into government equity stakes after finding private investments to match the government’s money.

The investment into the CBD oil company is bittersweet, in that it’s obviously great news for the recipient and great to see the United Kingdom recognize the economic potential of the merging cannabis industry, however, to some degree it highlights the deficiencies of the United Kingdom’s medical cannabis program.

As we previously reported, out of an estimated 1.4 million suffering patients, only thousands of patients have been prescribed a cannabis product by the United Kingdom directly, or indirectly via a private medical practitioner.

Patients deserve unfettered safe access to all forms of effective medical cannabis, which is unfortunately not the case in the United Kingdom.

 

How Many UK Patients Are Being Privately Prescribed Cannabis?

The United Kingdom is a fairly rough place when it comes to safe access to medical cannabis. The country’s medical cannabis program is notoriously restrictive, leaving suffering patients with little to no options depending on the situation.

For starters, the number of medical products that are considered to be legal in the United Kingdom is very low. Raw flower is not available to patients, and patients are not permitted to cultivate their own cannabis.

The National Health Service only allows cannabis-based products. Below is the definition of what that involves, via the National Health Service’s website:

There are three broad requirements that a product should satisfy:

  • The product is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative
  • It is produced for medicinal use in humans; and
  • It is a product that is regulated as a medicinal product, or an ingredient of a medicinal product.

The definition is necessarily broad to take account of the range of preparations which are cannabis-based that have been used for therapeutic purposes and to ensure that raw products/ingredients and intermediate products are captured.This is essential to ensure that where there is a clinical need, a patient will be able to access appropriate cannabis-based medicines and/or products can be made to meet any prescription.

Patients can get a prescription for a cannabis-based product through the National Health Service (NHS), however, as of last summer only 3 prescriptions had reportedly been issued by NHS.

Filling the void left by the NHS is private prescriptions. The prescriptions can only be issued by clinicians listed on the Specialist Register of the General Medical Council, and even then, the products eligible for a prescription are limited.

According to a new report from Prohibition Partners, private prescriptions have risen in the last two years. Below is an excerpt from their report:

Based on Prohibition Partners’ calculations, which conservatively assume all quarters in 2021 are equal, the annual number of products for last year amounted to 23,466 – a 425% increase on 2020. Things are moving more quickly elsewhere in the UK. On the island of Jersey, with a population of just over 100,000 inhabitants, more than 2,000 prescriptions were filled from January 2019 up to late 2021.

To put the figures into perspective, Prohibition Partners estimates that there are as many as 1.4 million patients in the United Kingdom that would purchase medical cannabis products if they were able to.

With that in mind, the uptick in private prescriptions in the UK is welcomed news, however, the UK’s medical cannabis program still has a long way to go when it comes to improving safe access for suffering patients.

In addition to expanding the type of products that patients can acquire, such as raw flower, patients also need to be able to cultivate their own medicine if they choose to do so, among other much-needed improvements.

National Cannabis Awareness Campaign Launched In UK

BRITISH CANNABIS launches new awareness campaign for CBD products

It is not that the British don’t want cannabis reform. They do. It is just their government that does not want to move any faster for (fill in the blank) reason. This is not new. Majorities of populations are all moving into the cannabis reform column as political reform follows, sluggishly, behind.

BRITISH CANNABIS, however, an independently owned producer, manufacturer, and distributor of legal cannabis-derived products, has decided to educate the public about CBD (and of course their own products in the process). The campaign is part of a $650,000 marketing campaign to reach health-conscious British consumers over the age of 45.

It will be broadcast on the SKY and Channel 5 networks, marking the first time SKY has allowed cannabis advertising on its channel since 2019.

The company also began selling its products on eBay this month.

Changing Times

The British cannabis question generally, is in a strange place – namely still very much a grey area. London Mayor Sadiq Khan is moving forward with a pilot plan of decriminalization for London. Other areas may follow suit.

In the meantime, illegitimate operations are being raided by the police, including in abandoned buildings and (even more embarrassingly) in city centres.

Larger entities are beginning to establish themselves (like BRITISH CANNABIS) although it is still a hazardous business.

The ability to advertise is also a clear breakthrough in the entire discussion. This is still a contentious discussion just about everywhere in the American and European media markets.

Could it be that the British are finally evolving with the times?

A Long and Torturous Road

Patients are still finding it very difficult to access cannabis. Project TWENTY21, which was supposed to register 20,000 patients has, so far, only managed to enlist 2,000. Beyond that, it is still a game where only those with money can access cannabis anywhere near “legally” and that only after a major bureaucratic struggle.

Most consumers are still left out of the legal market.

Perhaps this is why the latest campaign is geared towards older consumers. They are the ones with the most money, although thanks to both Brexit and Covid, combined with rising oil prices, inflation shock is rife in the UK.

However, beyond such encouraging steps, there has been little news about the forward progression of reform in the UK so far this year.

For the latest updates on evolving cannabis business news and regulation, be sure to attend the International Cannabis Business Conference in Berlin and Zurich this summer!

Is Boris Johnson’s Government About To Do Right By Cannabis?

The government task force examining how to regulate the industry suggests that the Home Office is not the best place to stick the cannabis industry – but not much else.

Sadly, Monty Python is not still doing skits lampooning British culture and government anymore. Or even Spitting Image. Regardless, and even without caricature to highlight the worst idiocies, the trajectory of British cannabis reform so far has been laughably cartoonish (where it has not also cost lives and of course been equally Dickensian.)

All of this makes sense of course when one realizes that so far, it has been the British Home Office – a large department that covers many unpleasant things about British life that cannot be called anything vaguely societally acceptable – that has handled all things cannabinoid from a policy perspective.

That now is about to change.

According to several paragraphs about halfway through the Final Report by the very officially named Taskforce on Innovation, Growth and Regulatory Reform presented recently to the Prime Minister, there needs to be a reform of the entire system in the UK. Further, that the regulation of medical cannabinoids should move to the Department of Health and Social Care as well as the Medicines and Healthcare products Regulatory Agency.

That said, the change in cannabinoid policy appears to be an afterthought, and further, tacked on a document that is heavy on the Brexit cheerleading and lacking a bit on fact-based reality – even about its characterization of the cannabis industry generally in the much-despised EU next door.

This starts with a characterization of all of this innovation now being allowed to flourish under the rubric of Brexit – if not setting the vaunted British Isles free of the “regulation of the continent.”

While there is clearly a problem with regulation in the cannabis industry – namely a lack of a clear, cohesive policy on the same in any country in Europe – there are a few countries well ahead of the UK on cannabis policy which is further allowed by the flexibility of being part of the EU.

Further, it is one thing to tout fundamental medical reform on this score and another to achieve it – no matter whether one is a country or an “island.” See Canada, where even after patients won the right to access the drug under a Supreme Court order, it took another 12 years to finally implement government agencies tasked with that kind of oversight.

So, while there is clearly regulatory change afoot for the industry that is likely to clarify the status of cannabinoids – at least as a medical drug – don’t expect anything so earth-shaking as say, Portugal, a member of the EU (or beyond that Luxembourg) are doing as of 2022. Or even Germany, which legalized the drug for medical purposes right around Brexit was being decided at the polls.

But you have to give them their due. The Brexiteers finally found cannabinoids. Now let’s see what they really do with them.

Be sure to book your tickets to the next International Cannabis Business Conference when it returns this summer to Berlin!